Sacubitril
Sacubitril is a medication used in combination with valsartan to treat heart failure. It is specifically indicated for patients with chronic heart failure who have reduced ejection fraction, a measure of the percentage of blood leaving the heart each time it contracts. Sacubitril is classified as a neprilysin inhibitor. Neprilysin is an enzyme that breaks down natriuretic peptides, which are hormones that help to regulate blood pressure and fluid balance. By inhibiting neprilysin, sacubitril increases the levels of these peptides, leading to reduced blood pressure and decreased fluid overload, which are beneficial effects in heart failure management.
Mechanism of Action
Sacubitril does not directly lower blood pressure or improve heart function. Instead, it works by inhibiting the enzyme neprilysin, which is responsible for the degradation of natriuretic peptides such as atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP), and C-type natriuretic peptide (CNP). These peptides play a crucial role in cardiovascular homeostasis by promoting natriuresis (the excretion of sodium in urine), diuresis (increased urine production), and vasodilation (widening of blood vessels). The inhibition of neprilysin by sacubitril leads to increased levels of these peptides, thereby exerting beneficial effects in patients with heart failure.
Clinical Use
Sacubitril, in combination with valsartan (marketed under the brand name Entresto), is approved for the treatment of heart failure with reduced ejection fraction. Clinical trials have demonstrated that this combination is more effective in reducing the risk of cardiovascular death and hospitalization for heart failure than angiotensin-converting enzyme inhibitors (ACE inhibitors) or angiotensin II receptor blockers (ARBs) alone.
Side Effects
The most common side effects of sacubitril/valsartan include hypotension (low blood pressure), hyperkalemia (high potassium levels in the blood), and renal impairment. Patients may also experience dizziness, cough, and fatigue. Due to the risk of angioedema (swelling under the skin), sacubitril/valsartan is not recommended for patients with a history of angioedema related to previous therapy with ACE inhibitors or ARBs.
Contraindications
Sacubitril/valsartan is contraindicated in patients with a history of angioedema related to previous therapy with ACE inhibitors or ARBs. It is also contraindicated in patients with hypersensitivity to any component of the medication. Due to the risk of fetal harm, sacubitril/valsartan should not be used during pregnancy.
Pharmacokinetics
Sacubitril is administered orally. It is a prodrug that is converted to its active form, LBQ657, by esterases in the blood. The combination of sacubitril and valsartan has a synergistic effect, with valsartan blocking the effects of angiotensin II, a potent vasoconstrictor, and sacubitril enhancing the levels of natriuretic peptides.
Conclusion
Sacubitril, particularly when used in combination with valsartan, represents a significant advancement in the treatment of heart failure with reduced ejection fraction. By inhibiting neprilysin and enhancing the effects of natriuretic peptides, it offers a novel approach to managing this condition, with clinical trials demonstrating its superiority over traditional therapies in reducing cardiovascular death and hospitalization for heart failure.
Transform your life with W8MD's budget GLP-1 injections from $125.
W8MD offers a medical weight loss program to lose weight in Philadelphia. Our physician-supervised medical weight loss provides:
- Most insurances accepted or discounted self-pay rates. We will obtain insurance prior authorizations if needed.
- Generic GLP1 weight loss injections from $125 for the starting dose.
- Also offer prescription weight loss medications including Phentermine, Qsymia, Diethylpropion, Contrave etc.
NYC weight loss doctor appointments
Start your NYC weight loss journey today at our NYC medical weight loss and Philadelphia medical weight loss clinics.
- Call 718-946-5500 to lose weight in NYC or for medical weight loss in Philadelphia 215-676-2334.
- Tags:NYC medical weight loss, Philadelphia lose weight Zepbound NYC, Budget GLP1 weight loss injections, Wegovy Philadelphia, Wegovy NYC, Philadelphia medical weight loss, Brookly weight loss and Wegovy NYC
WikiMD's Wellness Encyclopedia |
Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD